Veppanu (vepdegestrant) Approved for ER+/HER2- Metastatic Breast Cancer

FDA approved Veppanu on 5/1 for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations. This marks the first success of the heterobifunctional protein degradation class.